Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Transferases
Reexamination Certificate
1999-03-02
2001-05-15
Wax, Robert A. (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Transferases
C424S094200, C435S188000, C435S232000
Reexamination Certificate
active
06231854
ABSTRACT:
TECHNICAL FIELD
The present invention relates to expression modules that encode and express high levels of recombinant methioninase, recombinant methioninase produced using high-level expression modules, compositions containing recombinant methioninase produced using high-level expression modules, methods for purifying recombinant methioninase produced using high-level expression modules, chemically modified forms of recombinant methioninase, and methods of using recombinant methioninase produced using high-level expression modules in antimethionine and antihomocysteine therapy.
BACKGROUND
Therapeutic drug-based treatment of cancer is directed at the use of medicinals which selectively inhibit or kill the cancer cells while not harming normal tissue function beyond acceptable amounts. The difficulty with conventional chemotherapy has been the toxicity of therapeutic drugs for normal tissue.
Many tumors have been shown to have absolute requirement for methionine in a variety of cell types and evaluated tumor tissues, including tumors of the colon, breast prostate, ovary, kidney, larynx melanoma, sarcoma, lung, brain, stomach and bladder as well as leukemias and lymphomas. Methionine dependence has been defined as an inability of tumors to grow when methionine is replaced by homocysteine in the growth medium. See, for example, Chello et al.,
Cancer Res.,
33:1898-1904, 1973; and Hoffman,
Anticancer Res.,
5:1-30, 1985.
Methionine depletion has been shown to selectively synchronize methionine-dependent tumor cells into late S/G
2
phase of the cell cycle. Hoffman et al,
Proc. Natl. Acad. Sci. USA,
12:7306-7310, 1980. Using the combination of methionine deprivation, followed by repletion of methionine coupled with exposure to an antimitotic agent, termed antimethionine chemotherapy, tumor cells have been selectively eliminated from cocultures of normal and tumor cells, resulting in cultures of normal cells proliferating vigorously. Stern et al.,
J. Natl. Cancer Inst.,
76:629-639, 1986.
However, in order for methionine-dependent chemotherapy to, be conducted in vivo, it is necessary to have a means to effectively deplete serum of circulating methionine. Methionine depletion methods have not been described that reduce circulating methionine levels in vivo in a manner sufficient to be effective in antitumor therapies.
Methioninase, an enzyme which degrades methionine, has been purified from a variety of bacterial sources, and has been reported to slow the rate of tumor cell proliferation in vitro. Kreis et al.,
Cancer Res.,
33:1862-1865, and 1866-1869, 1973; Tanaka et al.,
FEBS Letters,
66:307-311 1976; Ito et al.,
J. Biochem.
79:1263-1272, 1976; and Nakayama et al.,
Agric. Biol. Chem.
48:2367-2369, 1984.
Kreis et al.,
Cancer Res.
33:1866-1869, 1973, have described the use of highly impure methioninase preparations isolated from
Clostridium sporgenes
at 1150 units/kg/day to inhibit growth of carcinosarcoma cells implanted in a mouse model. Although the enzyme apparently reduced primary tumor cell growth, it was not reported to reduce the T/C (treated versus control) ratio of tumor diameter below 50%, and was not reported to have any effect on metastasis. The authors also indicated that tumor specificity of the methioninase cannot be expected without other unspecified interventions, and further do not comment on the possibly that endotoxin, or other components of the impure preparation, were responsible for the effects observed. The only toxicity studies, reported were absence of animal body weight loss after the duration of the treatment, and negative gross examination for toxicity. Further, the authors report that the enzyme had a serum half life of 4 hours.
Kreis et al.,
Cancer Res.
33:1866-1869, 1973, further reported the use of a methionine-free diet as a means to deplete methionine as an antitumor therapy. However, the authors reported that the diet did not slow tumor growth as effectively as the use of an impure preparation of methioninase and resulted in the undesirable side effect of continuous loss of weight of the animal. The authors did not report the use of methionine deficient diets combined with methioninase treatment, and did not study cell synchronization.
The priority applications of the present invention disclose effective chemotherapy of tumors directed at effectively reducing the amount of methionine as to provide a beneficial antitumor effect without deleterious injury using methioninase. The present invention improves the disclosed therapeutic and diagnostic methods and composition by providing a source for producing commercially viable quantities of highly pure recombinant methioninase.
BRIEF DESCRIPTION OF THE INVENTION
The present invention is based, in part, on the generation of high-level expression modules encoding methioninase. The expression modules of the present invention produce recombinant methioninase in an appropriate host cell, such as
E. coli,
at levels ranging from about 5-75% of total cellular protein.
Based on this observation, the invention provides high expression modules encoding methioninase that expresses unexpectedly high levels of recombinant methioninase. High expression modules, such as those utilizing the T7 RNA polymerase promoter, have been used to produce recombinant methioninase at about 1 to 4 gram/liter with a specific activity of about 2 to 4 units/mg, before purification, using appropriate incubation conditions and purification methods.
The invention further provides methods of accurately selecting transformants containing high-level expression modules encoding methioninase for the ability to produce high levels of recombinant methioninase. Such procedures can be used to specifically select transformants containing recombinant methioninase-encoding DNA molecules isolated from an organism that naturally produces methioninase, as well as to identify transformants that express altered forms of a recombinant methioninase-encoding DNA molecule that increases the level of expression in a given host or the activity of the recombinant methioninase produced.
The invention further provides methods of producing recombinant methioninase using cells containing high-level expression modules encoding methioninase. The present invention further provides methods of purifying methioninase to obtain a highly pure, endotoxin free methioninase.
The invention further provides substantially pure recombinant methioninase produced using cells containing high-level expression modules encoding methioninase.
The present invention further provides methioninase in crystallized form.
The invention further provides compositions for diagnostic and therapeutic use that contain recombinant methioninase produced using a high-level expression module encoding methioninase.
The invention further provides methods for inhibiting tumor cell growth using the recombinant methioninase of the present invention.
The invention further provides the recombinant methioninase, of the present invention in chemically modified forms, such as by coupling of the recombinant methioninase to polymers such as polyethylene glycol (PEG).
The recombinant methioninase of the present invention can further be used to lower homocysteine levels in patients to reduce the risk of, and to treat, cardiovascular diseases.
The recombinant methioninase of the present invention can further be used to deplete methionine for tumor diagnosis and imaging.
Other features, advantages and related embodiments of the present invention will be apparent based on the disclosures contained herein.
REFERENCES:
patent: 94/11535 (1994-05-01), None
patent: 96/40284 (1996-12-01), None
Kreis et al.,Cancer Research(1973), 33:1862-1865.
Berezov, T.T. et al., “An improved prodcedure for isolation and purification of methionie gamma-lyase fromPseudomonas putida,” Voprosy Meditsinskoi Khimii (1983), vol. 29, No. 4, pp. 131-135.*
Tan et al., “Overexpression and large-scale production of recombinant 1 -methionine-alpha-deamino-gamma-mercaptone than-lyase....”, Protein Expression and Purification, vol.
Anticancer Inc.
Morrison & Foerster / LLP
Wax Robert A.
LandOfFree
Methioninase formulations and use in diagnostic methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methioninase formulations and use in diagnostic methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methioninase formulations and use in diagnostic methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2565672